Publication - Progress report

New Medicines Reviews 2013

Published: 3 May 2013
Part of:
Health and social care
ISBN:
9781782565604

Reports on the role of SMC & Review of IPTR & ADTC

91 page PDF

324.6 kB

91 page PDF

324.6 kB

Contents
New Medicines Reviews 2013
Appendix 3: Breakdown of NHS boards' ADTC decisions

91 page PDF

324.6 kB

Appendix 3: Breakdown of NHS boards' ADTC decisions

The table below Indicates each board's breakdown of medicines into the six decision categories

ADTC decision categories*
Board 1 2 3 4 5 6
NHS A&A 15 (65%) 2 (9%) 0 (0%) 2 (9%) 1 (4%) 3 (13%)
NHS Borders 17 (74%) 0 (0%) 1 (4%) 1 (4%) 0 (0%) 4 (17%)
NHS D&G 8 (35%) 5 (22%) 3 (13%) 0 (0%) 3 (13%) 4 (17%)
NHS Fife 21 (91%) 0 (0%) 0 (0%) 1 (4%) 1 (4%) 0 (0%)
NHS FV 20 (87%) 0 (0%) 0 (0%) 3 (13%) 0 (0%) 0 (0%)
NHS Grampian 14 (61%) 1 (4%) 0 (0%) 2 (9%) 6 (26%) 0 (0%)
NHS GG&C 20 (87%) 0 (0%) 0 (0%) 0 (0%) 0 (0%) 3 (13%)
NHS Highland 15 (65%) 0 (0%) 0 (0%) 8 (35%) 0 (0%) 0 (0%)
NHS Lanarkshire 23 (100%) 0 (0%) 0 (0%) 0 (0%) 0 (0%) 0 (0%)
NHS Lothian 11 (48%) 2 (9%) 0 (0%) 3 (13%) 3 (13%) 4 (17%)
NHS Orkney No Data Provided - as per NHS Grampian
NHS Shetland No Data Provided - as per NHS Grampian
NHS Tayside 18 (78%) 0 (0%) 0 (0%) 3 (13%) 0 (0%) 2 (9%)
NHS WI 15 (65%) 0 (0%) 0 (0%) 8 (35%) 0 (0%) 0 (0%)
Average 16 medicines 1 medicines 0 medicine 3 medicines 1 medicine 2 medicines
Average % 70% 4% 0% 13% 4% 9%

* ADTC decision categories:

  1. Included on the NHS board formulary (to include specialist, approved, additional lists) for the indication in question.
  2. Included pending protocol.
  3. Not included* from the NHS board formulary because the NHS board decision is that the medicine does not represent sufficient added benefit to other comparator medicines to treat the condition in question which are already available in the formulary.
  4. Not included* from the NHS board formulary because clinicians do not support the formulary inclusion.
  5. Not included* from the NHS board formulary because clinicians have not responded to an invitation to apply for formulary inclusion for this medicine;
  6. Not included* pending protocol.

Contact

Email: VERONICA MOFFAT